Roche and
Trimeris file for approval of needle-free administration of
Fuzeon

Drugmakers Roche and Trimeris on Monday filed for Food and Drug Administration approval of the Biojector 2000, a needle-free injection system to administer their HIV fusion inhibitor Fuzeon. The Biojector 2000, developed by Bioject Medical Technologies, works by using a carbon dioxide cartridge to power an intense spray of medication that penetrates the skin. The device has been available since 1996 and has been approved to administer several other medications that require subcutaneous or intramuscular administration. The drug companies say they expect a decision by the FDA later this year.